Uncategorized Adaptive Phage Therapeutics Initiates Phase 1/2 Trial of PhageBank 4 Jun 2021 Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the first patient has been dosed in a Phase 1/2 study…
PHAGElogist 